Beta-adrenoblocker nebivolol in the new Russian guidelines on arterial hypertension

1. E. Agabiti Rosei, D. Rizzoni. Metabolic Profile of Nebivolol, a p-Adrenoceptor Antagonist with Unique Characteristics//Drugs 2007; 67 (8):1097-107.

2. E. Ambrosioni, C. Borghi Tolerability of nebivolol in clinical trials comparing it with other selective beta-blockers is the treatment of hypertension. Ameta-analysis//High Blood Press & Cardiovascular Prevention 2005; 12(l):27-35.

3. Predel H.G., Mainka W., Schillings W., et al. Integrated effects of the vasodilating beta-blocker nebivolol on exercise performance, energy metabolism, cardiovascular and neurohormonal parameters in physically active patients with arterial hypertension//J Hum Hypertens 2001; 15 (10):715-21.

4. Flather M.D., Shibata M.C., Coats A.J., et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admissionin elderly patients withheartfailure (SENIORS)//Eur Heart J 2005; 26 (3): 215-25. SENIORS, data on file. In: The Proceedings of the World Congress of Cardiology; 2006 Sept. 2-6, Barcelona.

5. Celik T., Iyisoy A., Kursaklioglu H., et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients//J Hypertens 2006; 24 (3):591-6.

6. A.C. Schmidt, C. Graf, K. Brixius, J. Scholze. Blood pressure-lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus. The YESTONO Study//Clinical Drug Investigation 2007; 27 (12):841-9.